Seroprevalence of Bordetella pertussis in the Mexican population: A cross-sectional study

Epidemiology and Infection

Volumn 142, Issue 4, 2014, Pages 706-713

  Conde Glez, C ^a   Lazcano Ponce, E ^a   Rojas, R ^a   DeAntonio, R ^b   Romano Mazzotti, L ^c   Cervantes, Y ^c   Ortega Barria E ^d  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b GSK   (Belgium)

^c GLAXOSMITHKLINE   (Mexico)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bordetella pertussis; cocoon strategy; Mexico; pertussis toxin; seroprevalence; waning immunity

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENDER; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; PERTUSSIS; SEROPREVALENCE; SEX DIFFERENCE; SOCIAL STATUS; BACTERIAL TRANSMISSION; BACTERIUM CARRIER; BLOOD SAMPLING; DISEASE CLASSIFICATION; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; INFECTION SENSITIVITY; MEXICAN; BLOOD; CHI SQUARE DISTRIBUTION; EPIDEMIOLOGY; IMMUNOLOGY; INFANT; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

BACTERIUM ANTIBODY; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; MALE; MEXICO; MIDDLE AGED; PERTUSSIS VACCINE; SEROEPIDEMIOLOGIC STUDIES; WHOOPING COUGH; YOUNG ADULT;

EID: 84901710124     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813001313     Document Type: Article

References (39)

1. Guiso N, Liese J, Plotkin S. The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. Human Vaccines 2011; 7: 481-488.
2. Ulloa-Gutierrez R, Carvajal-Riggioni D, Baltodano A. Pertussis: should we improve intensive care management or vaccination strategies? Expert Review of Vaccines 2011; 10: 49-53.
3. WHO. Pertussis vaccines: WHO position paper.Weekly Epidemiological Record 2010; 85: 385-400.
4. Black RE, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 1969-1987.
5. WHO. Immunization profile (http://apps.who.int/immunization-monitoring/ en/globalsummary/country profileresult.cfm?C=mex). Accessed 10 February 2012.
6. Ulloa-Gutierrez R, Avila-Aguero ML. Pertussis in Latin America: current situation and future vaccination challenges. Expert Review of Vaccines 2008; 7: 1569-1580.
7. Santos JI. El programa nacional de vacunacion: orgulla de Mexico (http://www.ejournal.unam.mx/rfm/no45-3/RFM45308.pdf). Accessed 8 February 2012.
8. Ulloa-Gutierrez R, et al. The Global Pertussis Initiative: meeting report from the regional Latin America meeting, Costa Rica, 5-6 December, 2008. Human Vaccines 2010; 6: 876-880.
9. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatric Infectious Disease Journal 2005; 24: S10-S18.
10. Guiso N, et al. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine 2011; 29: 1115-1121.
11. Rendi-Wagner P, et al. The seroepidemiology of Bordetella pertussis in Israel - estimate of incidence of infection. Vaccine 2010; 28: 3285-3290.
12. Heininger U, Cherry JD. Pertussis immunization in adolescents and adults - Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opinion on Biological Therapy 2006; 6: 685-697.
13. Expert group on vaccinations for pertussis. Consensus on the clinical and microbiologic diagnosis of Bordetella pertussis and infection prevention. Salud Publica de Mexico 2011; 53: 57-65.
14. Olaiz-Fernández G, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2006. (http://www.insp.mx/ensanut/ensanut2006.pdf). Accessed 2 April 2013.
15. Riffelmann M, et al. Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Journal of Clinical Microbiology 2010; 48: 4459-4463.
16. Inandi T, Guraksin A, Hacialioglu N. Seroprevalence of pertussis among children in Eastern Turkey. Public Health 2005; 119: 550-555.
17. Chiu TF, et al. Pertussis seroepidemiology in Taipei. Journal of the Formosan Medical Association 2000; 99: 224-228.
18. Giammanco A, et al. Seroepidemiology of pertussis in Italy. Reviews of Infectious Diseases 1991; 13: 1216-1220.
19. National Institute of Statistics, Geography and Informatics. Population and Household Census. Mexico, 2010. Census sample. Database. (http://www.censo2010. org.mx/). Accessed 2 April 2013.
20. Halperin BA, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clinical Infectious Diseases 2011; 53: 885-892.
21. Esen B, et al. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. Journal of Clinical Laboratory Analysis 2007; 21: 154-161.
22. WHO. The immunological basis for immunization series: module 4: pertussis - update 2009 (http://whqlibdoc.who.int/publications/2010/9789241599337- eng.pdf). Accessed 10 February 2012.
23. Libster M, Edwards KM. Re-emergence of pertussis: what are the solutions? Expert Review of Vaccines 2012; 11: 1331-1346.
24. Guerrero ML, et al. Pertussis in adolescents in Mexico City: a prospective cohort study. Presented at the 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), Melbourne, Australia, 16-19 November 2011 (http://www.kenes.com/wspid2011/abstracts/pdf/235.pdf). Accessed 16 March 2012.
25. Cattaneo LA, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons aged 1-65 years. Journal of Infectious Diseases 1996; 173: 1256-1259.
26. De Melker HE, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. Journal of Clinical Microbiology 2000; 38: 800-806.
27. De Melker HE, et al. The incidence of Bordetella pertussis infection estimated in the population from a combination of serological surveys. Journal of Infection 2006; 53: 106-113.
28. Olin P, et al. Randomized controlled trial of twocomponent, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the study of pertussis vaccines. Lancet 1997; 350: 1569-1577.
29. De Greef SC, et al. Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 2010; 5: e14183.
30. Pebody RG, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and Infection 2005; 133: 159-171.
31. Brooks DA, Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. Journal of the American Board of Family Medicine 2006; 19: 603-611.
32. Hallander HO, et al. Seroprevalence of pertussis toxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2009; 117: 912-922.
33. Versteegh FGA, et al. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiology and Infection 2005; 133: 737-748.
34. Valdespino JL, et al. Seroepidemiology of hepatitis A in Mexico. A detector of social inequity and monitor of immunization policies. Salud Publica de Mexico 2007; 49 (Suppl. 3): S377-S385.
35. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clinical Infectious Diseases 2011; 52: 157-162.
36. Castagnini LA, et al. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clinical Infectious Diseases 2012; 54: 78-84.
37. Skowronski DM, et al. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clinical Infectious Diseases 2012; 54: 318-327.
38. Munoz F, Englund J. Infant pertussis: Is cocooning the answer? Clinical Infectious Diseases 2011; 53: 893-896.
39. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP). Morbidity and MortalityWeekly Report 2011; 60: 1424-1426.